5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.
about
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesBeyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationRecent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activityMelanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers.Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.5α-reductase type 1 modulates insulin sensitivity in men.Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.Bisphenol A exposure during adulthood alters expression of aromatase and 5α-reductase isozymes in rat prostateGenetic defects in dolichol metabolism.Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.A review of the carcinogenic potential of bisphenol A.Current status of 5α-reductase inhibitors in prostate disease managementMinireview: Androgen metabolism in castration-resistant prostate cancer.Is the Expression of Androgen Receptor Protein Associated With the Length of AC Repeats in the Type III 5-α Reductase Gene in Prostate Cancer Patients?Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.Metabolic dysfunction in female mice with disruption of 5α-reductase 1Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implicationsPersistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.5α-reductase type 3 enzyme in benign and malignant prostate.Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsImpact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.Steroid hormone synthetic pathways in prostate cancer.Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.Androgen pathway manipulation and survival in patients with lung cancer.
P2860
Q21285041-A0B8A8A4-66F5-406E-A21F-9E9D6B26BBC4Q27007208-395E0D31-64D9-476B-99E8-CAEF47DA1AC9Q33623428-BE03A478-47B4-4958-8A46-31C56981A5A9Q33775717-653532A0-41D0-42FC-BDB1-CA5B330DC6DBQ34064040-CFCFB193-6BFC-4D12-B0F6-7F1FCF370543Q34110419-8C650AE0-DB16-41AC-9E5A-58041F490C9DQ34189517-7B122527-9B85-4414-8CFB-9077F1FFCA85Q34313140-730AA956-53B2-4707-838B-4A43BF72DD84Q34313221-F8FFEA99-41C3-41A1-A4B5-EBF56BC3E989Q34396472-D8DF6A7E-08F5-4CAD-BA65-D8AA286E5F71Q34448181-AB104AAF-0E0B-4CC5-BABE-C041DFB08373Q34584590-4C31C677-BC49-48E9-BF3C-7CB2244B5539Q34798492-3D9690F0-F86B-4B97-8425-F54A168E5EDDQ35223874-6D2494E5-3F81-4726-A70A-90AE74D54C31Q36665050-C2108CD7-BCF7-4AF9-A120-D61FA2F4C82DQ36778346-F39531BB-F370-4291-8C4E-A012E0123368Q36789277-9B3D9FD3-6FD9-463A-A1DD-BC0DEB006726Q36937716-A0613E17-4E24-4198-9EC6-D1C599AB513EQ37076775-6F0A38A7-4B73-4063-AD0D-317EF2BD9D06Q37428499-C6DA2A19-81B8-48CC-B395-0241A1ECBE6AQ37639218-2DF22A77-6B17-43D1-91CD-AB2CB9E64525Q37694089-B8355C51-454B-48B5-82CA-66C00DAB0797Q37709925-EAE3B83E-5AFB-4178-84AC-31DD28E90DCCQ37712234-4413D79E-88A1-489D-B3D0-D09840501140Q37723393-E7F9BD4E-E779-41EE-9679-EA7DB5375EC3Q38212470-91ECE379-4AC8-46EB-8EF9-A2A6F83E4B94Q38239520-C5D9391C-A8ED-4D0E-993D-A7A4B099DAD7Q38266059-6BFD1DE6-11B0-4F5C-A159-F1611DCDBF07Q46748110-65DECE1F-E048-47B2-B52C-CFA8D6307130Q47756626-785B2A48-1F5D-4209-A69E-68CE4FCCDEDBQ52655045-532FC92D-F71B-4665-BF44-90CD7BABCFAAQ53576123-B0BECA50-25B8-4AB4-B94D-D7680A4EE534
P2860
5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
5α-reductase type 3 expression ...... g prostate cancer progression.
@ast
5α-reductase type 3 expression ...... g prostate cancer progression.
@en
5α-reductase type 3 expression ...... g prostate cancer progression.
@nl
type
label
5α-reductase type 3 expression ...... g prostate cancer progression.
@ast
5α-reductase type 3 expression ...... g prostate cancer progression.
@en
5α-reductase type 3 expression ...... g prostate cancer progression.
@nl
prefLabel
5α-reductase type 3 expression ...... g prostate cancer progression.
@ast
5α-reductase type 3 expression ...... g prostate cancer progression.
@en
5α-reductase type 3 expression ...... g prostate cancer progression.
@nl
P2093
P2860
P356
P1433
P1476
5α-reductase type 3 expression ...... g prostate cancer progression.
@en
P2093
Alejandro Godoy
Borislav Alexiev
Elzbieta Kawinski
Faris Azzouni
James L Mohler
Mark A Titus
P2860
P304
P356
10.1002/PROS.21318
P577
2010-12-28T00:00:00Z